The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Omalizumab for asthma in adults and children
Open accessAbstract
BACKGROUND: Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It is called an 'anti-IgE' drug. IgE is an immune mediator involved in clinical manifestations of asthma. A recent update of National Institute for Health and Care Excellence (NICE) guidance in 2013 recommends omalizumab for use as add-on therapy in adults and children over six years of age with inadequately controlled severe persistent allergic IgE-mediated asthma who require continuous or frequent treatment with oral corticosteroids. OBJECTIVES: To assess the effects of omalizumab versus placebo or conventional therapy for asthma in adults and children. SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register of trials for potentially relevant studies. The most recent search was performed in June 2013. We also checked the reference lists of included trials and searched online trial registries and drug company websites. SELECTION CRITERIA: Randomised controlled trials examining anti-IgE administered in any manner for any duration. Trials with co-interventions were included, as long as they were the same in each arm. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study quality and extracted and entered data. Three modes of administration were identified from the published literature: inhaled, intravenous and subcutaneous injection. The main focus of the updated review is subcutaneous administration, as this route is currently used in clinical practice. Subgroup analysis was performed by asthma severity. Data were extracted from published and unpublished sources. MAIN RESULTS: In all, 25 trials were included in the review, including 11 new studies since the last update, for a total of 19 that considered the efficacy of subcutaneous anti-IgE treatment as an adjunct to treatment with corticosteroids.For participants with moderate or severe asthma who were receiving background inhaled corticosteroid steroid (ICS) therapy, a significant advantage favoured subcutaneous omalizumab with regard to experiencing an asthma exacerbation (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.42 to 0.60; ten studies, 3261 participants). This represents an absolute reduction from 26% for participants suffering an exacerbation on placebo to 16% on omalizumab, over 16 to 60 weeks. A significant benefit was noted for subcutaneous omalizumab versus placebo with regard to reducing hospitalisations (OR 0.16, 95% CI 0.06 to 0.42; four studies, 1824 participants), representing an absolute reduction in risk from 3% with placebo to 0.5% with omalizumab over 28 to 60 weeks. No separate data on hospitalisations were available for the severe asthma subgroup, and all of these data were reported for participants with the diagnosis of moderate to severe asthma. Participants treated with subcutaneous omalizumab were also significantly more likely to be able to withdraw their ICS completely than those treated with placebo (OR 2.50, 95% CI 2.00 to 3.13), and a small but statistically significant reduction in daily inhaled steroid dose was reported for omalizumab-treated participants compared with those given placebo (weighted mean difference (WMD) -118 mcg beclomethasone dipropionate (BDP) equivalent per day, 95% CI -154 to -84). However, no significant difference between omalizumab and placebo treatment groups was seen in the number of participants who were able to withdraw from oral corticosteroid (OCS) therapy (OR 1.18, 95% CI 0.53 to 2.63).Participants treated with subcutaneous omalizumab as an adjunct to treatment with corticosteroids required a small but significant reduction in rescue beta2-agonist medication compared with placebo (mean difference (MD) -0.39 puffs per day, 95% CI -0.55 to -0.24; nine studies, 3524 participants). This benefit was observed in both the moderate to severe (MD -0.58, 95% CI -0.84 to -0.31) and severe (MD -0.30, 95% CI -0.49 to -0.10) asthma subgroups on a background therapy of inhaled corticosteroids; however, no significant difference between subcutaneous omalizumab and placebo was noted for this outcome in participants with severe asthma who were receiving a background therapy of inhaled plus oral corticosteroids. Significantly fewer serious adverse events were reported in participants assigned to subcutaneous omalizumab than in those receiving placebo (OR 0.72, 95% CI 0.57 to 0.91; 15 studies, 5713 participants), but more injection site reactions were observed (from 5.6% with placebo to 9.1% with omalizumab).To reflect current clinical practice, discussion of the results is limited to subcutaneous use, and trials involving intravenous and inhaled routes have been archived. AUTHORS' CONCLUSIONS: Omalizumab was effective in reducing asthma exacerbations and hospitalisations as an adjunctive therapy to i
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
British Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to Allergens
Burrows, B., Martinez, F. D., Halonen, M., Barbee, R. A., & Cline, M. G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902023200502 · Cited by 1,659
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
IMMUNOLOGIC BASIS OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS
Wills-Karp, M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.255 · Cited by 1,020
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Sears, M. R., Burrows, B., Flannery, E. M., Herbison, G. P., Hewitt, C. J., & Holdaway, M. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110103251504 · Cited by 796
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants
Blanken, M. O., Rovers, M. M., Molenaar, J. M., Winkler-Seinstra, P. L., Meijer, A., Kimpen, J. L. L., & Bont, L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211917 · Cited by 671
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Hanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
Boulet, L. P., Chapman, K. R., Côté, J., Kalra, S., Bhagat, R., Swystun, V. A., Laviolette, M., Cleland, L. D., Deschesnes, F., Su, J. Q., et al. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196083 · Cited by 399
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00223411 · Cited by 373
Bilgiç Temel, A., Bassorgun, C. I., Akman-Karakaş, A., Alpsoy, E., & Uzun, S. (2017) · Case Reports in Dermatology · doi:10.1159/000452828 · Cited by 363
Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★
Casale, T. B., Bernstein, I. L., Busse, W. W., LaForce, C. F., Tinkelman, D. G., Stoltz, R. R., Dockhorn, R. J., Reimann, J., Su, J. Q., & Fick Jr., R. B. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70202-1 · Cited by 326
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
Bousquet, J., Rabe, K., Humbert, M., Chung, K. F., Berger, W., Fox, H., Ayre, G., Chen, H., Thomas, K., Blogg, M., et al. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.01.011 · Cited by 304
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Corren, J., Busse, W., Meltzer, E. O., Mansfield, L., Bensch, G., Fahrenholz, J., Wenzel, S. E., Chon, Y., Dunn, M., Weng, H. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1448oc · Cited by 299
Effect of Nebulized Ipratropium on the Hospitalization Rates of Children with Asthma
Qureshi, F., Pestian, J., Davis, P., & Zaritsky, A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391503 · Cited by 294
TREATMENT OF ALLERGIC ASTHMA WITH MONOCLONAL ANTI-IgE ANTIBODY
Ilgrom, H. E. M., Ick, R. O. B. F., Ohn, J., Eimann, J. A. D. R., Ush, R. O. K. B., Arc, M., Atrous, L. W., Ames, W. J., & Roup, S. T. G. (1999) · Cited by 281
Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00533.x · Cited by 279
Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma
Bousquet, J., Wenzel, S., Holgate, S., Lumry, W., Freeman, P., & Fox, H. (2004) · Chest · doi:10.1378/chest.125.4.1378 · Cited by 277
Anti-IgE for chronic asthma in adults and children
Walker, S., Monteil, M., Phelan, K., Lasserson, T. J., & Walters, E. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub3 · Cited by 236
Self-citationMassanari, M., Nelson, H., Casale, T., Busse, W., Kianifard, F., Geba, G. P., & Zeldin, R. K. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.022 · Cited by 230
Garcia, G., Magnan, A., Chiron, R., Contin-Bordes, C., Berger, P., Taillé, C., Devouassoux, G., de Blay, F., Couderc, L.-J., Didier, A., et al. (2013) · Chest · doi:10.1378/chest.12-1961 · Cited by 206
Brusselle, G., Michils, A., Louis, R., Dupont, L., Van de Maele, B., Delobbe, A., Pilette, C., Lee, C. S., Gurdain, S., Vancayzeele, S., et al. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.06.014 · Cited by 201
Berger, W., Gupta, N., McAlary, M., & Fowler-Taylor, A. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62175-8 · Cited by 182
Kopp, M. V., Hamelmann, E., Zielen, S., Kamin, W., Bergmann, K. ‐., Sieder, C., Stenglein, S., Seyfried, S., Wahn, U., & for the DUAL study group (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03121.x · Cited by 181
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., Champain, K., Fox, H., Thirlwell, J., & Della Cioppa, G. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00278102 · Cited by 179
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma
Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., & Gupta, N. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.54 · Cited by 173
Noga, O., Hanf, G., Brachmann, I., Klucken, A. C., Kleine-Tebbe, J., Rosseau, S., Kunkel, G., Suttorp, N., & Seybold, J. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.028 · Cited by 170
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
Bousquet, J., Siergiejko, Z., Świebocka, E., Humbert, M., Rabe, K. F., Smith, N., Leo, J., Peckitt, C., Maykut, R., & Peachey, G. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02522.x · Cited by 168
After 6 years with Xolair; a 3‐year withdrawal follow‐up
Nopp, A., Johansson, S. G. O., Adédoyin, J., Ankerst, J., Palmqvist, M., & Öman, H. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02144.x · Cited by 166
Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma
Hoshino, M., & Ohtawa, J. (2012) · Respiration · doi:10.1159/000334701 · Cited by 164
Buhl, R., Hanf, G., Solèr, M., Bensch, G., Wolfe, J., Everhard, F., Champain, K., Fox, H., & Thirlwell, J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00016502 · Cited by 160
Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects
FAHY, J. V., COCKCROFT, D. W., BOULET, L.-P., WONG, H. H., DESCHESNES, F., DAVIS, E. E., RUPPEL, J., SU, J. Q., & ADELMAN, D. C. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9810012 · Cited by 158
Parker, J. M., Oh, C. K., LaForce, C., Miller, S. D., Pearlman, D. S., Le, C., Robbie, G. J., White, W. I., White, B., & Molfino, N. A. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-14 · Cited by 156
Determinants of Different Dimensions of Disease Severity in Asthma and COPD
Wijnhoven, H. A. H., Kriegsman, D. M. W., Hesselink, A. E., Penninx, B. W. J. H., & de Haan, M. (2001) · CHEST Journal · doi:10.1378/chest.119.4.1034 · Cited by 151
Slavin, R. G., Ferioli, C., Tannenbaum, S. J., Martin, C., Blogg, M., & Lowe, P. J. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.050 · Cited by 148
Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma
Lemanske, R. F., Nayak, A. S., McAlary, M., Everhard, F., FowlerTaylor, A., & Gupta, N. (2002) · PEDIATRICS · doi:10.1542/peds.110.5.e55 · Cited by 148
Holgate, S. T., Bousquet, J. J., Wenzel, S. E., Fox, H., Liu, J., & Castellsagué, J. (2001) · Current Medical Research and Opinion · doi:10.1185/0300799019117010 · Cited by 129
Perret, J. L., Dharmage, S. C., Matheson, M. C., Johns, D. P., Gurrin, L. C., Burgess, J. A., Marrone, J., Markos, J., Morrison, S., Feather, I., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201205-0788oc · Cited by 128
Self-citationCost‐effectiveness of omalizumab in patients with severe persistent allergic asthma
Brown, R. E., Turk, F., Dale, P., & Bousquet, J. J. (2007) · Allergy · doi:10.1111/j.1398-9995.2006.01310.x · Cited by 120
Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge
Eckman, J. A., Sterba, P. M., Kelly, D., Alexander, V., Liu, M. C., Bochner, B. S., MacGlashan, D. W., & Saini, S. S. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.012 · Cited by 117
Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti‐IgE treatment
van Rensen, E. L. J., Evertse, C. E., van Schadewijk, W. A. A. M., van Wijngaarden, S., Ayre, G., Mauad, T., Hiemstra, P. S., Sterk, P. J., & Rabe, K. F. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01881.x · Cited by 114
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
Kulus, M., Hébert, J., García, E., Taylor, A. F., Vidaurre, C. F., & Blogg, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003771338 · Cited by 102
Ong, Y. E., Menzies-Gow, A. N., Barkans, J. R., Benyahia, F., Ou, T.-T., Sun, Y., & Kay, A. B. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.035 · Cited by 97
Effect of omalizumab in health care workers with occupational latex allergy
Leynadier, F., Doudou, O., Gaouar, H., Gros, V., Bourdeix, I., Guyomarch-Cocco, L., & Trunet, P. F. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.11.020 · Cited by 93
Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma
Castro, M., Rubin, A. S., Laviolette, M., Hanania, N. A., Armstrong, B., & Cox, G. (2011) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2011.03.005 · Cited by 91
Efficacy and safety of omalizumab in an Asian population with moderate‐to‐severe persistent asthma
Ohta, K., Miyamoto, T., Amagasaki, T., Yamamoto, M., & on behalf of the 1304 Study Group (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01633.x · Cited by 90
Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients
Siergiejko, Z., Świebocka, E., Smith, N., Peckitt, C., Leo, J., Peachey, G., & Maykut, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.620950 · Cited by 89
Omalizumab-induced decrease of FcɛRI expression in patients with severe allergic asthma
Chanez, P., Contin‐Bordes, C., Garcia, G., Verkindre, C., Didier, A. P., Frederic de, B. L. A. Y., de Lara, M. T., Blanco, P., Moreau, J., Robinson, P., et al. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.07.011 · Cited by 88
Niven, R. M., Chung, K. F., Panahloo, Z., Blogg, M., & Ayre, G. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.06.002 · Cited by 88
Omalizumab: Clinical Use for the Management of Asthma
Thomson, N. C., & Chaudhuri, R. (2012) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s7793 · Cited by 86
Kamin, W., Kopp, M., Erdnuess, F., Schauer, U., Zielen, S., & Wahn, U. (2009) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2009.00900.x · Cited by 82
Johansson, S. G. O., Nopp, A., Öman, H., Ankerst, J., Cardell, L., Grönneberg, R., Matsols, H., Rudblad, S., Strand, V., & Stålenheim, G. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02051.x · Cited by 80
Relationship between pretreatment specific IgE and the response to omalizumab therapy
Wahn, U., Martín, C., Freeman, P., Blogg, M., & Jimenez, P. A. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02119.x · Cited by 75
Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
Milgrom, H., FowlerTaylor, A., Vidaurre, C. F., & Jayawardene, S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.539502 · Cited by 73
Update on optimal use of omalizumab in management of asthma
Pelaia, G. (2011) · Journal of Asthma and Allergy · doi:10.2147/jaa.s14520 · Cited by 72
Hodsman, P., Ashman, C., Cahn, A. P., Boever, E. H. D., Locantore, N., Serone, A., & Pouliquen, I. J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04334.x · Cited by 61
Bardelas, J. A., Figliomeni, M., Kianifard, F., & Meng, X. (2012) · Journal of Asthma · doi:10.3109/02770903.2011.648296 · Cited by 60
Humbert, M. J. C., Boulet, L. P., Niven, R. M., Panahloo, Z., Blogg, M., & Ayre, G. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01846.x · Cited by 60
Rubin, A. S., Souza‐Machado, A., Andradre-Lima, M., Ferreira, F. N. H., Honda, A., Matozo, T. M., & On behalf of the QUALITX Study Investigators (2012) · Journal of Asthma · doi:10.3109/02770903.2012.660297 · Cited by 48
Humbert, M. J. C., Berger, W. L., Rapatz, G., & Turk, F. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01654.x · Cited by 47
Zielen, S., Lieb, A., Motte, S. D. L., Wagner, F. D., de Monchy, J., Fuhr, R., Munzu, C., Koehne‐Voss, S., Rivière, G., Kaiser, G., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000339243 · Cited by 46
Effect of Omalizumab on Adenosine 5′-Monophosphate Responsiveness in Subjects with Allergic Asthma
Prieto, L. M., Gutiérrez, V., Colás, C., Tabar, A. I., Pérez‐Francés, C., Bruno, L., & Uixera, S. (2005) · International Archives of Allergy and Immunology · doi:10.1159/000090387 · Cited by 43
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge
Corren, J., Wood, R. A., Patel, D., Zhu, J., Yegin, A., Dhillon, G., & Fish, J. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.043 · Cited by 38
Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma
Ayars, A. G., Altman, L. C., Potter‐Perigo, S., Radford, K., Wight, T. N., & Nair, P. K. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000343031 · Cited by 38
Self-citationEffects of anti-IgE in asthmatic subjects
Frew, A. J. (1998) · Thorax · doi:10.1136/thx.53.2008.s52 · Cited by 35
Babu, K. S., Arshad, S. H., & Holgate, S. T. (2001) · Allergy · doi:10.1034/j.1398-9995.2001.00019.x · Cited by 34
Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease
Berger, W. E. (2002) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61989-8 · Cited by 26
Rivière, G., Yeh, C. M., Reynolds, C., & Brookman, L. J. (2011) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.1000075 · Cited by 26
Karpel, J. P., Massanari, M. J., Geba, G. P., Kianifard, F., Inhaber, N., & Zeldin, R. K. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.09.011 · Cited by 24
Brain magnetic resonance imaging in adults with asthma
Parker, J., Wolansky, L. J., Khatry, D., Geba, G. P., & Molfino, N. A. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.09.006 · Cited by 23
Omalizumab: An update on efficacy and safety in moderate-to-severe allergic asthma
Chipps, B. E., Figliomeni, M., & Spector, S. L. (2012) · Allergy and Asthma Proceedings · doi:10.2500/aap.2012.33.3599 · Cited by 21
Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab
Chen, H., Eisner, M. D., Haselkorn, T., & Trzaskoma, B. L. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.09.008 · Cited by 20
Allergic inflammation in upper and lower airways
Spector, S. L. (1999) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)62848-7 · Cited by 20
Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Massanari, M. J., Kianifard, F., Zeldin, R. K., & Geba, G. P. (2009) · Allergy and Asthma Proceedings · doi:10.2500/aap.2009.30.3245 · Cited by 13
Luskin, A. T., Kosinski, M. R., Bresnahan, B. W., Ashby, M. A., & Wong, D. A. (2005) · Journal of Asthma · doi:10.1080/02770900500369868 · Cited by 12
Harnest, U., Boulet, L., Hedgecock, S., Blogg, M., Surrey, K., & Fox, H. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.01.067 · Cited by 3
Dahl, R., Ayres, J. G., Hedgecock, S., Blogg, M., Surrey, K., & Fox, H. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.12.090 · Cited by 2
The Effect of Discontinuing Omalizumab Therapy on Free IgE Concentration
Lowe, P. J., Jaffe, J., Martín, C., Brookman, L. J., & Fox, H. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.040 · Cited by 2
Corren, J., Wood, R. A., Patel, D. B., Zhu, J., & Fish, J. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.282 · Cited by 2
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
New developments in mast cell biology
Kalesnikoff, J., & Galli, S. J. (2008) · Nature Immunology · doi:10.1038/ni.f.216 · Cited by 748
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Metadata
- Authors
- Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-01-13
- Volume
- 2014
- Issue
- 1
- Pages
- CD003559-CD003559
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1501757022
- Cited by
- 651
- References
- 99
- FWCI
- 36.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.